Bioavailability and variability of biphasic insulin mixtures

European Journal of Pharmaceutical Sciences

Volumn 46, Issue 4, 2012, Pages 198-208

  Søeborg, Tue ^a   Rasmussen, Christian Hove ^a,b   Mosekilde, Erik ^b   Colding Jorgensen, Morten ^a  

^a NOVO NORDISK A S   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Absorption kinetics; Insulin crystals; NPH insulin; Rapid acting insulin analogue; Subcutaneous depot

Indexed keywords

BIPHASIC INSULIN; HUMAN INSULIN; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; PIG INSULIN;

ADIPOCYTE; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW VELOCITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG SOLUBILITY; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEGRADATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SKIN BLOOD FLOW; SUBCUTANEOUS TISSUE;

ABSORPTION; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; CRYSTALLIZATION; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN, ISOPHANE; MODELS, BIOLOGICAL; SUBCUTANEOUS TISSUE; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION;

EID: 84861201685     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.06.005     Document Type: Article

References (90)

1. P. Balschmidt, F. Hansen, E.J. Dodson, G.G. Dodson, and F. Korber Structure of porcine insulin cocrystallized with clupeine Z Acta Crystallogr. B 47 1991 975 986
2. R. Becker, and A.D. Frick Clinical pharmacokinetics and pharmacodynamics of insulin glargine Clin. Pharmacokinet. 47 2008 7 20 (Pubitemid 350260885)
3. M. Berger, P. Halban, L. Girardier, J. Seydoux, R. Offord, and A. Renold Absorption kinetics of subcutaneously injected insulin. Evidence for degradation at the injection site Diabetologia 17 1979 97 99 (Pubitemid 9212205)
4. C. Binder Absorption of injected insulin Acta Pharmacol. Toxicol. 27 Suppl. 2 1969 5 84
5. W. Bocian, J. Sitkowski, A. Tarnowska, E. Bednarek, R. Kawecki, W. Kozminski, and L. Kozerski Direct insight into insulin aggregation by 2D NMR complemented by PFGSE NMR Proteins 71 2008 1057 1065 (Pubitemid 351564033)
6. J. Brange, D.R. Owens, S. Kang, and A. Volund Monomeric insulins and their experimental and clinical implications Diabetes Care 13 1990 923 954 (Pubitemid 20260734)
7. D.N. Brems, L.A. Alter, M.J. Beckage, R.E. Chance, R.D. DiMarchi, L.K. Green, H.B. Long, A.H. Pekar, J.E. Shields, and B.H. Frank Altering the association properties of insulin by amino acid replacement Protein Eng. 5 1992 527 533
8. D. Brooke Dissolution profile of log-normal powders: exact expression J. Pharm. Sci. 62 1973 795 798
9. Brunfeldt, K.; Poulsen, J.; 1953. Protamine-splitting enzyme from serum and subcutaneous tissue. Reports of the Steno Memorial Hospital and the Nordisk Insulinlaboratorium, vol. 5, pp. 51-61.
10. S. Charman, D. McLennan, G. Edwards, and C. Porter Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model Pharm. Res. 18 2001 1620 1626 (Pubitemid 33022420)
11. J.W. Chen, T. Lauritzen, J.J. Christiansen, L.H. Jensen, W.H.O. Clausen, and J.S. Christiansen Pharmacokinetic profiles of biphasic insulin aspart 30/70 and 70/30 in patients with type 1 diabetes: a randomized double-blinded crossover study Diabet. Med. 22 2004 273 277
12. S. Claessen, and T. Mortensen Den lokale blodgennemstromning i subcutis' betydning for insulinabsorption 2009 Technical University of Denmark Copenhagen
13. W. Clausen, A. De Gaetano, and A. Volund Within-patient variation of the pharmacokinetics of subcutaneously injected biphasic insulin aspart as assessed by compartmental modelling Diabetologia 49 2006 2030 2038 (Pubitemid 44168469)
14. D. Crandall, G. Hausman, and J. Kral A review of the microcirculation of adipose tissue: anatomic, metabolic and anigiogenic perspectives Microcirculation 4 1997 211 232 (Pubitemid 127674006)
15. T. Deckert Subcutaneous degradation of insulin Diabetologia 21 1981 161 162 (Pubitemid 11085855)
16. European Medicines Agency. Insulatard. European Public Assessment Report, http://www.emea.europa.eu/humandocs/Humans/EPAR/insulatard/insulatard.htm (accessed 03.04.09).
17. U. Fischer, E.J. Freyse, E. Jutzi, W. Besch, M. Raschke, S. Hofer, and G. Albrecht Absorption rates of subcutaneously injected insulin in the dog as calculated from the plasma insulin levels by means of a simple mathematical model Diabetologia 24 1983 196 201 (Pubitemid 13147825)
18. A. Florence, and D. Attwood Physicochemical Principles of Pharmacy third ed. 1998 Macmillan Press Ltd. Ebbw Vale
19. S.J. Friedberg, Y.W.F. Lam, J.J. Blum, and R.I. Gregerman Insulin absorption: a major factor in apparent insulin resistance and the control of type 2 diabetes mellitus Metabolism 55 2006 614 619
20. J.A. Galloway, M. Root, R. Rathmacher, and R. Carmichael A comparison of acid regular and neutral regular insulin Diabetes 22 1973 471 479
21. J.A. Galloway, C.T. Spradlin, R.L. Nelson, S.M. Wentworth, J.A. Davidson, and J.L. Swarner Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures Diabetes Care 4 1981 366 376 (Pubitemid 12201586)
22. A.J. Garber Premixed insulin analogues for the treatment of diabetes mellitus Drugs 66 2006 31 49 (Pubitemid 43144962)
23. A. Giacca, A. Caumo, G. Galimberti, G. Petrella, M.C. Librenti, M. Scavini, G. Pozza, and P. Micossi Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects J. Clin. Endocrinol. Metab. 77 1993 738 742 (Pubitemid 23298658)
24. L.A. Goeders, L.A. Esposito, and M.E. Peterson Absorption kinetics of regular and isophane (NPH) insulin in the normal dog Domest. Anim. Endocrinol. 4 1987 43 50
25. O. Gonzalez, R.L. Smith, and S.B. Goodman Effect of size, concentration, surface area, and volume of polymethylmethacrylate particles on human macrophages in vitro J. Biomed. Mater. Res. 30 1996 463 473 (Pubitemid 26107079)
26. G. Graham The use of a mixture of ordinary and protamine insulin Acta Med. Scand. Suppl. 90 1937 54 63
27. D. Greenblatt, and J. Koch-Wesser Clinical pharmacokinetics. Part II N. Engl. J. Med. 293 1975 964 970
28. H. Hagedorn On the protamine splitting properties of blood serum Skand. Arch. Physiol. 80 1938 156 163
29. Hagedorn, H.; 1946. The absorption of protamine insulin. Reports of the Steno Memorial Hospital and the Nordisk Insulinlaboratorium, vol. 1, pp. 25-28.
30. R.N. Hansen Glucose Homeostasis. A Biosimulation Approach 2004 Technical University of Denmark Copenhagen
31. C. Hedman, T. Lindström, and H. Arnqvist Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes Diabetes Care 24 2001 1120 1121
32. L. Heinemann, C. Weyer, M. Rauhaus, S. Heinrichs, and T. Heise Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart Diabetes Care 21 1998 1910 1914 (Pubitemid 28478292)
33. L. Heinemann Variability of insulin absorption and insulin action Diabetes Technol. Ther. 4 2002 673 682 (Pubitemid 35283332)
34. L. Heinemann Variability of insulin action: does it matter? Insulin 3 2008 37 45 (Pubitemid 351331168)
35. T. Heise, U. Eckers, K. Kanc, J.N. Nielsen, and L. Nosek The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study Diabetes Technol. Ther. 10 2008 479 485
36. T. Heise, C. Weyer, A. Serwas, S. Heinrichs, J. Osinga, P. Roach, J. Woodworth, U. Gudat, and L. Heinemann Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin Diabetes Care 21 1998 800 803 (Pubitemid 28487075)
37. T. Heise, L. Heinemann, U. Hövelmann, B. Brauns, L. Nosek, H.L. Haahr, and K.J. Olsen Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and basal-bolus therapy Diabetes Care 32 2009 1431 1433
38. H. Hewitt The mechanics of subcutaneous injection Br. J. Exp. Pathol. 35 1954 35 40
39. P. Hildebrandt, P. Sejrsen, S. Nielsen, K. Birch, and L. Sestoft Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients Scand. J. Clin. Lab. Invest. 45 1985 685 690 (Pubitemid 16235891)
40. P. Hildebrandt, K. Birch, L. Sestoft, and S.L. Nielsen Orthostatic changes in subcutaneous blood flow and insulin absorption Diabetes Res. 2 1985 187 190 (Pubitemid 16240178)
41. P. Home, L. Barriocanal, and A. Lindholm Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers Eur. J. Clin. Pharmacol. 55 1999 199 203 (Pubitemid 29244647)
42. R. Hori, F. Komada, S. Iwakawa, Y. Seino, and K. Okumura Enhanced bioavailability of subcutaneously injected insulin coadministered with collagen in rats and humans Pharm. Res. 6 1989 813 816 (Pubitemid 19247853)
43. R. Hori, F. Komada, and K. Okumura Pharmaceutical approach to subcutaneous dosage forms of insulin J. Pharm. Sci. 72 1983 435 439 (Pubitemid 13118663)
44. C. Houtzagers, P. Berntzen, H. van der Stap, R. Heine, and E. van der Veen Absorption kinetics of short- and intermediate-acting insulins after jet injection with Medi-Jector II Diabetes Care 11 1988 739 742
45. D.C. Howey, R.R. Bowsher, R.L. Brunelle, and J.R. Woodworth [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin Diabetes 43 1994 396 402 (Pubitemid 24064246)
46. A. Hübinger, W. Weber, W. Jung, K. Wehmeyer, and F.A. Gries The pharmacokinetics of two different concentrations of short-acting insulin, intermediate-acting insulin, and an insulin mixture following subcutaneous injection Clin. Invest. 70 1992 621 626
47. S. Hvidt Insulin association in neutral solutions studied by light scattering Biophys. Chem. 39 1991 205 213
48. L. Kagan, P. Gershkovich, A. Mendelman, S. Amsili, N. Ezov, and A. Hoffman The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model Eur. J. Pharm. Biopharm. 67 2007 759 765 (Pubitemid 47576609)
49. B28) in healthy subjects Diabetes Care 14 1991 1057 1065
50. T. Kobayashi, S. Sawano, T. Itoh, K. Kosaka, H. Hirayama, and Y. Kasuya The pharmacokinetics of insulin after continuous subcutaneous infusion or bolus subcutaneous injection in diabetic patients Diabetes 32 1983 331 336 (Pubitemid 13161906)
51. K. Kolendorf, J. Bojsen, and S.L. Nielsen Adipose tissue blood flow and insulin disappearance from subcutaneous tissue Clin. Pharmacol. Ther. 25 1979 598 604 (Pubitemid 9208918)
52. E. Kraegen, and D. Chisholm Insulin responses to varying profiles of subcutaneous insulin infusion: kinetic modelling studies Diabetologia 26 1984 208 213 (Pubitemid 14167802)
53. P. Kurtzhals, and U. Ribel Action profile of cobalt(III)-insulin. A novel principle of protraction of potential use for basal insulin delivery Diabetes 44 1995 1381 1385
54. T. Lauritzen Pharmacokinetic and Clinical Aspects of Intensified Subcutaneous Insulin Therapy 1985 University of Copenhagen Copenhagen
55. J. Li, and Y. Kuang Systematically modeling the dynamics of plasma insulin in subcutaneous injection of insulin analogues for type 1 diabetes Math. Biosci. Eng. 6 2009 41 58
56. Y. Li, Z. Shao, and A.K. Mitra Dissociation of insulin oligomers by bile salt micelles and its effect on alpha-chymotrypsin-mediated proteolytic degradation Pharm. Res. 9 1992 864 869
57. M. Lin, and C.K. Larive Detection of insulin aggregates with pulsed-field gradient nuclear magnetic resonance spectroscopy Anal. Biochem. 229 1995 214 220
58. B. Linde, and G. Chisholm The interstitial space of adipose tissue as determined by single injection and equilibration techniques Acta Physiol. Scand. 95 1975 383 390
59. J. Markussen, S. Havelund, P. Kurtzhals, A.S. Andersen, J. Halstrom, E. Hasselager, U.D. Larsen, U. Ribel, L. Schäffer, K. Vad, and I. Jonassen Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs Diabetologia 39 1996 281 288 (Pubitemid 26064823)
60. D. McLennan, C. Porter, and S. Charman Subcutaneous drug delivery and the role of the lymphatics Drug Discov. Today: Technol. 2 2005 89 96 (Pubitemid 40946313)
61. M. Miyazaki, H. Mukai, K. Iwanaga, K. Morimoto, and M. Kakemi Pharmacokinetic-pharmacodynamic modelling of human insulin: validity of pharmacological availability as a substitute for extent of bioavailability J. Pharm. Pharmacol. 53 2001 1235 1246 (Pubitemid 32904018)
62. E. Mosekilde, K. Jensen, C. Binder, S. Pramming, and B. Thorsteinsson Modeling absorption kinetics of subcutaneously injected soluble insulin J. Pharmacokinet. Biopharm. 17 1989 67 87 (Pubitemid 19111990)
63. S.R. Mudaliar, F.A. Lindberg, M. Joyce, P. Beerdsen, P. Strange, A. Lin, and R.R. Henry Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects Diabetes Care 22 1999 1501 1506 (Pubitemid 29418246)
64. J. Neal Analysis of effectiveness of human U-500 insulin in patients unresponsive to conventional insulin therapy Endocr. Pract. 11 2005 305 307
65. C. Nicholson, and E. Sykova Extracellular space structure revealed by diffusion analysis Trends Neurosci. 21 1998 207 215 (Pubitemid 28191815)
66. R. Nosadini, K.S. De, E. Duner, E. Iori, A. Avogaro, R. Trevisan, P. Fioretto, A. Doria, C. Merkel, and C. Cobelli Porcine and human insulin absorption from subcutaneous tissues in normal and insulin-dependent diabetic subjects: a deconvolution-based approach J. Clin. Endocrinol. Metab. 67 1988 551 559
67. R. Offord, J. Philippe, J. Davis, P. Halban, and M. Berger Inhibition of degradation of insulin by ophthalmic acid and by a bovine pancreatic proteinase inhibitor Biochem. J. 182 1979 249 251 (Pubitemid 9240684)
68. A. Oliva, J. Farina, and M. Llabres Development of two high-performance liquid chromatographic methods for the analysis and characterization of insulin and its degradation products in pharmaceutical preparations J. Chromatogr. B 749 2000 25 34
69. D.R. Owens Human Insulin first ed. 1986 MTP Press Ltd. Lancaster
70. P. Paulsen, J. Courtney III, and W. Duckworth Insulin resistance caused by massive degradation of subcutaneous insulin Diabetes 28 1979 640 645 (Pubitemid 9226264)
71. C. Porter, and S. Charman Lymphatic transport of proteins after subcutaneous administration J. Pharm. Sci. 89 2000 297 310 (Pubitemid 30152431)
72. J. Radziuk, J. Davies, W. Pye, J.E. Shields, R.D. DiMarchi, and R.E. Chance Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs - LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin assessed in a conscious pig model Diabetes 46 1997 548 556 (Pubitemid 27143369)
73. C. Rasmussen Subcutaneous Insulin Absorption 2009 Technical University of Denmark Lyngby, Denmark
74. W. Ravis, C. Comerci, and V. Ganjam Pharmacokinetics of insulin following intravenous and subcutaneous administration in canines Biopharm. Drug Dispos. 7 1986 407 420 (Pubitemid 16014519)
75. J. Schlichtkrull, O. Munck, and M. Jersild Insulin rapitard and insulin actrapid Acta Med. Scand. 177 1965 103 113
76. A. Sharkawy, B. Klitzman, G. Truskey, and W. Reichert Engineering the tissue which encapsulates subcutaneous implants: I. Diffusion properties J. Biomed. Mater. Res. 37 1997 401 412 (Pubitemid 27481455)
77. L. Shen, and Z. Chen Critical review of the impact of tortuosity on diffusion Chem. Eng. Sci. 62 2007 3748 3755 (Pubitemid 46891455)
78. T. Soeborg, C. Rasmussen, E. Mosekilde, and M. Colding-Jorgensen Absorption kinetics of insulin after subcutaneous administration Eur. J. Pharm. Sci. 36 2009 78 90
79. M. Takeyama, T. Ishida, N. Kokubu, F. Komada, S. Iwakawa, K. Okumura, and R. Hori Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors Pharm. Res. 8 1991 60 64
80. C. Tarín, E. Teufel, J. Picó, J. Bondia, and H.-J. Pfleiderer Comprehensive pharmacokinetic model of insulin glargine and other insulin formulations IEEE Trans. Biomed. Eng. 52 2005 1994 2005 (Pubitemid 41774878)
81. R.L. Thorisdottir, T. Parkner, J.W. Chen, N. Ejskjær, and J.S. Christiansen A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study Basic Clin. Pharmacol. Toxicol. 104 2009 216 221
82. K. Tokihiro, H. Arima, S. Tajiri, T. Irie, F. Hirayama, and K. Uekama Improvement of subcutaneous bioavailability of insulin by sulphobutyl ether β-cyclodextrin in rats J. Pharm. Pharmacol. 52 2000 911 917
83. Z. Trajanoski, P. Wach, P. Kotanko, A. Ott, and F. Skraba Pharmacokinetic model for the absorption of subcutaneously injected soluble insulin and monomeric insulin analogues Biomed. Tech. 38 1993 224 231 (Pubitemid 23291519)
84. W.K. Waldhäusl, P.R. Bratusch-Marrain, H. Vierhapper, and P. Nowotny Insulin pharmacokinetics following continuous infusion and bolus injection of regular porcine and human insulin in healthy man Metabolism 32 1983 478 486 (Pubitemid 13083653)
85. M.S. Wallace, M.E. Peterson, and C.E. Nichols Absorption kinetics of regular, isophane, and protamine zinc insulin in normal cats Domest. Anim. Endocrinol. 7 1990 509 515
86. R.M. Watanabe, A. Volund, and R.N. Bergman Intravenous insulin infusion to simulate subcutaneous absorption. Bioavailability and metabolic sequelae Diabetes Care 14 1991 1021 1030
87. C. Weyer, T. Heise, and L. Heinemann Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture Diabetes Care 20 1997 1612 1614 (Pubitemid 27415043)
88. J.L. Whittingham, D.J. Edwards, A.A. Antson, J.M. Clarkson, and G.G. Dodson Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro → Asp insulin analogues Biochemistry 37 1998 11516 11523 (Pubitemid 28388193)
89. G. Williams, J.C. Pickup, S. Bowcock, E. Cooke, and H. Keen Subcutaneous aprotinin causes local hyperaemia. A possible mechanism by which aprotinin improves control in some diabetic patients Diabetologia 24 1983 91 94 (Pubitemid 13191885)
90. X. Zhou, and A. Po Effects of cholic acid and other enhancers on the bioavailability of insulin from a subcutaneous site Int. J. Pharm. 69 1991 29 41